AstraZeneca

#AstraZeneca #Cell therapy #EsoBiotec #Mergers and acquisitions #Oncology

AstraZeneca buys in vivo cell therapy specialists EsoBiotec

AstraZeneca has revealed it will acquire EsoBiotec for a total consideration of up to $1 billion.  The acquisition includes the company’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the immune system to attack cancers.  ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T… Read More

#Business & Investment #News

Map of China
#AstraZeneca #China #Investment #Obesity #Weight loss

AZ expands China operations, agrees obesity deal with CSPC

AstraZeneca has agreed a new strategic collaboration agreement with China’s CSPC Pharmaceuticals to develop multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.   Under this agreement, the companies will initially progress four programmes, which utilise CSPC's AI-driven peptide drug discovery platform and its LiquidGel once-monthly dosing platform… Read More

#Business & Investment #News #Trending News

#AstraZeneca #Clinical trial #Lupus

AstraZeneca’s lupus treatment shows positive results 

AstraZeneca’s Saphnelo (anifrolumab) has demonstrated strong results for the treatment of systemic lupus erythematosus (SLE).  In the Phase III TULIP-SC trial, 56.2% of patients who received Saphnelo via subcutaneous (SC) self-administration achieved a reduction in disease activity at Week 52 versus 37.1% receiving placebo, as measured by the British Isles Lupus Assessment Group-based Composite Lupus… Read More

#News

#Actithera #AstraZeneca #Radiopharmaceuticals

Actithera appoints new CMO to advance radiopharmaceuticals 

Radiopharmaceutical biotech company Actithera has appointed Darshan Dalal as Chief Medical Officer.  Dalal will lead the clinical strategy and build the clinical development organisation as Actithera advances its lead fibroblast activation protein (FAP)-targeting RLT into the clinic. The company is also building its pipeline of differentiated precision-engineered radiopharmaceuticals.  Dalal… Read More

#News

#Artificial intelligence (AI) #AstraZeneca #Business #Cell therapy #Google #Immunotherapy

DDW Highlights: 28 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, Galapagos announced plans to shelve its cell therapy business and hundreds of… Read More

#Podcasts

Woman with a nose bleed
#Amgen #AstraZeneca #European Union

Tezspire approved in EU for ‘challenging’ rhinosinusitis  

AstraZeneca and Amgen’s Tezspire (tezepelumab) has been approved in the European Union for chronic rhinosinusitis with nasal polyps.  Tezspire has been approved as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard… Read More

#News #Regulatory

#Artificial intelligence (AI) #AstraZeneca #Business #Cell therapy #DDW Turning Science into Business Symposium #Google #Immunotherapy

This week in Drug Discovery (20 – 24 October)

News round-up for 20 – 24 October by Bruno Quinney, Content Team at DDW.  This week’s leading story comes from biotech, with Galapagos announcing plans to shelve its cell therapy business and hundreds of employees set to lose theirjobs. Elsewhere, pharma firms are offering discounts to US… Read More

#News

#AstraZeneca #Biopharma #Direct-to-Consumer #Pfizer #Pharmaceutical industry #United States

Pharma firms offer discounts of up to 85% to US patients

AstraZeneca has become the latest company to lower the cost of medicines for American patients. The company recently announced an agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients “while preserving America’s cutting-edge biopharmaceutical innovation”.  In July, US President Donald Trump sent letters… Read More

#Business & Investment #Editor's Choice #News

UK financial markets
#AstraZeneca #Drug development #Investment #UK

AstraZeneca halts £200m research investment in UK 

AstraZeneca has halted its planned £200 ($270) million investment in a research facility in Cambridge, UK, according to reports from Reuters.  The investment, which was anticipated to generate 1,000 new jobs, is currently on hold.  The pharmaceutical company's decision indicates that none of its newly announced funding, initially revealed in… Read More

#Business & Investment #News

Pascal Soriot, Chief Executive Officer, AstraZeneca
#AstraZeneca #Investment #Metabolic diseases #New facility #United States

AstraZeneca invests $50b in US, plans new chronic disease centre

AstraZeneca will invest $50 billion in the United States by 2030, following similar announcements by other big pharma companies.   The company says the investment will create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients… Read More

#Business & Investment #News

Scientist conducts tests in the lab
#AstraZeneca #Haematology #Monoclonal antibodies #Phase III trial

AZ’s anselamimab fails to meet primary endpoint in amyloidosis trial

High-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical programme show that anselamimab did not achieve statistical significance for the primary endpoint compared to placebo in patients with Mayo stages IIIa and IIIb light chain (AL) amyloidosis.   The primary endpoint was defined… Read More

#News

Bladder
#AstraZeneca #Bladder cancer #European Commission #Monoclonal antibodies #Oncology

EU-approved bladder cancer therapy reduces death risk by 25%

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment.  According to the decision, this treatment should be followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery… Read More

#Cancer Research #News #Regulatory

Lungs
#Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Lung cancer #Oncology

First TROP2-directed therapy approved in the US for lung cancer

Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).  It is approved in patients who have received prior EGFR-directed therapy and platinum-based chemotherapy.  The indication was approved under accelerated approval based… Read More

#News #Regulatory #Trending News

Patient using a mammography machine
#AstraZeneca #Breast cancer #Cancer Research UK #Gene mutation #Oncology

New approach shows promise in aggressive breast cancers

A clinical trial for early-stage breast cancer patients with BRCA gene mutations has reported 100% survival after three years.  In a Phase III trial, Cancer Research UK researchers stopped BRCA-linked breast cancers growing or coming back by giving patients olaparib tablets 48 hours after each chemotherapy dose. … Read More

#Cancer Research #News #Trending News

Leukaemia
#AstraZeneca #Blood cancer #European Commission #Leukaemia #Oncology

Fixed-duration Calquence-based regimens approved in EU

A fixed-duration regimen of AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for previously untreated chronic lymphocytic leukaemia (CLL).  The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human… Read More

#News #Regulatory

Breast cancer
#ASCO #AstraZeneca #Breast cancer #Oncology #The Institute of Cancer Research

Camizestrant reduces risk of breast cancer progression by 56%

Results of a global study presented at the American Society of Clinical Oncology (ASCO) annual meeting have shown that camizestrant for advanced breast cancer can be used to treat emerging tumours.  The study was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research,… Read More

#Cancer Research #News #Trending News